Nuo Therapeutics, Inc. has entered into an Assignment, Joinder, and Amendment No. 1 to its Amended and Restated Loan and Security Agreement, dated May 29, 2026. The amendment, effective October 6, 2026, extended the closing date for the second tranche of funding and facilitated the addition of new investors.
The Company successfully closed on the Second Funding of $325,000 on October 6, 2026. This brings the total aggregate funding received from Lenders to $2,000,000, consistent with the Company’s previous disclosure of a $2,000,000 total funding commitment. The funds were issued as Secured Promissory Notes bearing an annual interest rate of 12% and maturing on December 31, 2028. Interest is payable in warrants.
A portion of the $325,000 funding commitment was assigned to four new parties known as Assuming Lenders. These include three unaffiliated third parties and Scott M. Pittman, a member of the Board of Directors of Nuo Therapeutics and a beneficial owner of more than 10% of the Company’s common stock. Mr. Pittman previously provided $200,000 in the Initial Funding and $100,000 in the Interim Funding, and has now loaned an additional $25,000.
In connection with the assignment, the Company issued warrants to the Assuming Lenders. These include Second Restated Warrants exercisable for 18,000 shares of common stock, Prepayment Restated Warrants exercisable for 1,832 shares, and Interest Warrants exercisable for up to 11,000 shares at maturity. Mr. Pittman received specific warrants totaling 7,208 shares in the aggregate, including 4,500 Second Restated Warrants and 458 Prepayment Restated Warrants, along with an additional Interest Warrant for 2,750 shares.
The Amendment did not alter the exercise price, expiration date, or other material economic terms of the warrants as previously disclosed. The offer and sale of the warrants and underlying shares have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption.
